Jonathan Silverstein - Net Worth and Insider Trading

Jonathan Silverstein Net Worth

The estimated net worth of Jonathan Silverstein is at least $637 Million dollars as of 2024-04-23. Jonathan Silverstein is the Director, 10% Owner of Relypsa Inc and owns about 9,941,551 shares of Relypsa Inc (RLYP) stock worth over $318 Million. Jonathan Silverstein is the Director, 10% Owner of Audentes Therapeutics Inc and owns about 4,801,638 shares of Audentes Therapeutics Inc (BOLD) stock worth over $288 Million. Jonathan Silverstein is also the Director of Intercept Pharmaceuticals Inc and owns about 1,120,324 shares of Intercept Pharmaceuticals Inc (ICPT) stock worth over $21 Million. Besides these, Jonathan Silverstein also holds Arcutis Biotherapeutics Inc (ARQT) , resTORbio Inc (TORC) , Glaukos Corp (GKOS) . Details can be seen in Jonathan Silverstein's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Jonathan Silverstein has not made any transactions after 2020-10-02 and currently still holds the listed stock(s).

Transaction Summary of Jonathan Silverstein

To

Jonathan Silverstein Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Jonathan Silverstein owns 12 companies in total, including Arcutis Biotherapeutics Inc () , Avedro Inc () , and Glaukos Corp () among others .

Click here to see the complete history of Jonathan Silverstein’s form 4 insider trades.

Insider Ownership Summary of Jonathan Silverstein

Ticker Comapny Transaction Date Type of Owner
Arcutis Biotherapeutics Inc 2020-10-02 director & 10 percent owner
Avedro Inc 2019-11-21 director & 10 percent owner
Glaukos Corp 2018-03-06 director
scPharmaceuticals Inc 2017-11-16 director
Rhythm Pharmaceuticals Inc 2017-10-04 director & 10 percent owner
Sorrento Tech Inc 2016-09-21 director & 10 percent owner
Audentes Therapeutics Inc 2016-08-24 director & 10 percent owner
Intercept Pharmaceuticals Inc 2015-03-26 director
Relypsa Inc 2013-11-20 director & 10 percent owner
NxStage Medical Inc 2010-05-27 director & 10 percent owner
Insulet Corp 2007-05-14 director
Adicet Bio Inc 2018-01-25 director & 10 percent owner

Jonathan Silverstein Latest Holdings Summary

Jonathan Silverstein currently owns a total of 6 stocks. Among these stocks, Jonathan Silverstein owns 9,941,551 shares of Relypsa Inc (RLYP) as of November 20, 2013, with a value of $318 Million and a weighting of 49.93%. Jonathan Silverstein owns 4,801,638 shares of Audentes Therapeutics Inc (BOLD) as of July 25, 2016, with a value of $288 Million and a weighting of 45.21%. Jonathan Silverstein also owns 1,120,324 shares of Intercept Pharmaceuticals Inc (ICPT) as of March 26, 2015, with a value of $21 Million and a weighting of 3.34%. The other 3 stocks Arcutis Biotherapeutics Inc (ARQT) , resTORbio Inc (TORC) , Glaukos Corp (GKOS) have a combined weighting of 1.52% among all his current holdings.

Latest Holdings of Jonathan Silverstein

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
RLYP Relypsa Inc 2013-11-20 9,941,551 31.99 318,030,216
BOLD Audentes Therapeutics Inc 2016-07-25 4,801,638 59.97 287,954,231
ICPT Intercept Pharmaceuticals Inc 2015-03-26 1,120,324 19.00 21,286,156
ARQT Arcutis Biotherapeutics Inc 2020-10-02 902,286 8.96 8,084,483
TORC resTORbio Inc 2018-01-30 690,055 2.28 1,573,325
GKOS Glaukos Corp 2018-03-06 0 99.79 0

Holding Weightings of Jonathan Silverstein


Jonathan Silverstein Form 4 Trading Tracker

According to the SEC Form 4 filings, Jonathan Silverstein has made a total of 0 transactions in Relypsa Inc (RLYP) over the past 5 years. The most-recent trade in Relypsa Inc is the acquisition of 712,192 shares on November 20, 2013, which cost Jonathan Silverstein around $8 Million.

According to the SEC Form 4 filings, Jonathan Silverstein has made a total of 0 transactions in Audentes Therapeutics Inc (BOLD) over the past 5 years. The most-recent trade in Audentes Therapeutics Inc is the acquisition of 33,334 shares on July 25, 2016, which cost Jonathan Silverstein around $500,010.

According to the SEC Form 4 filings, Jonathan Silverstein has made a total of 0 transactions in Intercept Pharmaceuticals Inc (ICPT) over the past 5 years. The most-recent trade in Intercept Pharmaceuticals Inc is the sale of 157,200 shares on March 26, 2015, which brought Jonathan Silverstein around $45 Million.

More details on Jonathan Silverstein's insider transactions can be found in the Insider Trading History of Jonathan Silverstein table.

Insider Trading History of Jonathan Silverstein

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Jonathan Silverstein Trading Performance

GuruFocus tracks the stock performance after each of Jonathan Silverstein's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Jonathan Silverstein is 49.37%. GuruFocus also compares Jonathan Silverstein's trading performance to market benchmark return within the same time period. The performance of stocks bought by Jonathan Silverstein within 3 months outperforms 5 times out of 6 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Jonathan Silverstein's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Jonathan Silverstein

Average Return

57.97%

Average return per transaction

Outperforming Transactions

83%

5 out of 6 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 20.13 49.37 29.55 57.97 36.45 23.24
Relative Return to S&P 500(%) 23.07 49.96 22.87 42.85 25.66 13.18

Jonathan Silverstein Ownership Network

Ownership Network List of Jonathan Silverstein

No Data

Ownership Network Relation of Jonathan Silverstein


Jonathan Silverstein Owned Company Details

What does Arcutis Biotherapeutics Inc do?

Who are the key executives at Arcutis Biotherapeutics Inc?

Jonathan Silverstein is the director & 10 percent owner of Arcutis Biotherapeutics Inc. Other key executives at Arcutis Biotherapeutics Inc include SVP and Chief Business Officer Matthew Richard Moore , director & 10 percent owner Patrick J Heron , and director & President and CEO Todd Franklin Watanabe .

Arcutis Biotherapeutics Inc () Insider Trades Summary

Over the past 18 months, Jonathan Silverstein made no insider transaction in Arcutis Biotherapeutics Inc (). Other recent insider transactions involving Arcutis Biotherapeutics Inc () include a net sale of 30,155 shares made by Todd Franklin Watanabe , a net sale of 37,403 shares made by Howard G. Welgus , and a net sale of 10,594 shares made by Masaru Matsuda .

In summary, during the past 3 months, insiders sold 29,378 shares of Arcutis Biotherapeutics Inc () in total and bought 21,052 shares, with a net sale of 8,326 shares. During the past 18 months, 104,916 shares of Arcutis Biotherapeutics Inc () were sold and 102,515 shares were bought by its insiders, resulting in a net sale of 2,401 shares.

Arcutis Biotherapeutics Inc ()'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Arcutis Biotherapeutics Inc Insider Transactions

No Available Data

Jonathan Silverstein Mailing Address

Above is the net worth, insider trading, and ownership report for Jonathan Silverstein. You might contact Jonathan Silverstein via mailing address: 601 Lexington Avenue, 54th Floor, New York Ny 10022.

Discussions on Jonathan Silverstein

No discussions yet.